Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial of COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer

Trial Profile

A Phase I trial of COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs COTI 2 (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Nov 2018 According to a Cotinga Pharmaceuticals media release, the company has entered into a research collaboration with St. Vincent's University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer.
    • 09 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top